Currently, two radionuclide-conjugated antibodies are in trials for DSRCT: 131I-3F8, directed against GD2, which has previously been tested in medulloblastoma (50) and as a diagnostic tool in neuroblastoma (51), and 131I-8H9, directed against B7-H3, which has been previously tested in neuroblastoma (52). Here, CD276 is linked to neuroblastoma.